yian管理团队
-
A Best-in-Class Oral Small-Molecule GLP-1 Receptor Agonist with Superior Weight Loss and Appetite Suppression Efficacy | PharmaTimes BD Opportunity
On August 7, 2025, Eli Lilly reported its second-quarter financial results, which exceeded…
-
Approaching $6 Billion! XtalPi Secures Major Out-Licensing Agreement
On August 5, 2025, XtalPi Inc. entered into a collaboration agreement with Dovetree (a com…
-
Failure Against Placebo? Vertex Stumbles in Pursuit of Billion-Dollar Non-Opioid Analgesia Market
Vertex Pharmaceuticals faces renewed setbacks in its non-opioid analgesic pipeline. Its Na…
-
Has the mRNA Vaccine Era Collapsed? Kennedy Announces Cancellation of Funding for 22 mRNA Vaccine Projects
On August 5, 2025, Robert F. Kennedy Jr., the newly appointed U.S. Secretary of Health and…
-
A Potentially Best-in-Class (BIC) Pan-RAS (ON) Inhibitor with Superior PK Profile and Significant Pharmacological Efficacy
The RAS gene family—comprising KRAS, NRAS, and HRAS—is one of the most frequently mutated …
-
DrugTimes BD Project DT-084 | A GLP-1/GCG/GIP Triagonist for the Treatment of Obesity, Type 2 Diabetes, and Steatohepatitis
In recent years, dual- and triple-targeting agents acting on glucagon-like peptide-1 recep…
-
A Preclinical Menin-MLL Inhibitor for Acute Myeloid Leukemia (AML) Seeking Partners
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, characte…
-
Seeking Partners for a Bispecific Antibody Targeting IL4Rα/IL13 and IL31 for Atopic Dermatitis | DrugTimes BD Project
In the early clinical development of atopic dermatitis (AD), multiple inflammatory factors…
-
Several Pharma Giants Vie for Next-Gen Obesity and Diabetes Therapies
Semaglutide, a GLP-1 receptor agonist, can truly be described as a “breakout star…
-
药时代BD需求 | 多家药企寻找「差异化减重/降糖」创新药
司美格鲁肽（GLP-1受体激动剂）可谓“出道即巅峰”——不仅成功俘获了马斯克的“芳心”，还被《Science》杂志评为2023年全球十大科学突破之首。同年，它还跃升为美国最畅销的处…
